Lichen planus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lichen planus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris. https://clinicaltrials.eu/trial/a-study-of-upadacitinib-in-adults-with-erosive-mucosal-lichen-planus-and-lichen-planopilaris/ Wed, 29 Apr 2026 15:09:22 +0000 https://clinicaltrials.eu/trial/a-study-of-upadacitinib-in-adults-with-erosive-mucosal-lichen-planus-and-lichen-planopilaris/ This study focuses on individuals living with Lichen Planus, specifically the erosive mucosal type which affects the lining of the mouth, and Lichen Planopilaris, a condition that causes hair loss and scalp inflammation. The purpose of the study is to evaluate the effectiveness of a medication called upadacitinib. Participants will be assigned to receive either 30 mg of rinovq, which is a prolonged-release tablet designed to release the medicine slowly into the body, or a placebo.

During the study, participants will take one tablet daily. The process involves monitoring the condition over a period of time to see how the medication affects the symptoms and the overall health of the affected areas. The evaluation of the treatment continues through various stages to observe changes in the skin, hair, or mouth over several weeks.

]]> Study on the Effectiveness of Deucravacitinib for Patients with Lichen Planus https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-deucravacitinib-for-patients-with-lichen-planus/ Wed, 29 Apr 2026 14:25:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-deucravacitinib-for-patients-with-lichen-planus/ This clinical trial is focused on studying the effects of a medication called Deucravacitinib on patients with a skin condition known as Lichen Planus. Lichen Planus is a disease that causes swelling and irritation in the skin, hair, nails, and mucous membranes. The trial aims to evaluate how effective Deucravacitinib is in reducing the symptoms and activity of this disease. Deucravacitinib is a type of medication that works by selectively inhibiting a protein involved in the immune response, which may help in reducing inflammation and other symptoms associated with Lichen Planus.

Participants in the study will receive either Deucravacitinib or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will take place over several months, during which participants will have regular visits to monitor their condition and any changes in their symptoms. The goal is to see if Deucravacitinib can improve the clinical symptoms of Lichen Planus compared to the placebo.

The trial will involve multiple visits to assess the progress and any changes in the condition of the participants. These visits will help researchers understand the impact of Deucravacitinib on the disease and gather important data on its effectiveness and safety. The study is expected to provide valuable insights into the potential benefits of this medication for people suffering from Lichen Planus.

]]>